# Abivax S.A. clinical trials: 23 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Abivax S.A. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Abivax S.A.: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/abivax-s-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 6, 2026 | NCT07453784 | Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation | Abivax S.A. | Phase 1 | Recruiting | Healthy | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453784) |
| June 13, 2024 | NCT06456593 | Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | Abivax S.A. | Phase 2 | Recruiting | Moderately to Severely Active Crohn Disease | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06456593) |
| September 10, 2022 | NCT05535946 | ABTECT - Maintenance | Abivax S.A. | Phase 3 | Active not recruiting | Ulcerative Colitis | 1,116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05535946) |
| August 18, 2022 | NCT05507216 | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 | Abivax S.A. | Phase 3 | Completed | Ulcerative Colitis | 636 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05507216) |
| August 18, 2022 | NCT05507203 | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 | Abivax S.A. | Phase 3 | Completed | Ulcerative Colitis | 639 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05507203) |
| January 5, 2022 | NCT05177835 | Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis | Abivax S.A. | Phase 2 | Active not recruiting | Ulcerative Colitis | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05177835) |
| November 16, 2021 | NCT05121714 | Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 | Abivax S.A. | Phase 1 | Completed | Healthy | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05121714) |
| September 2, 2021 | NCT05032560 | Safety and Pharmacokinetics Study in Healthy Japanese Volunteers | Abivax S.A. | Phase 1 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05032560) |
| May 19, 2020 | NCT04393038 | ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 | Abivax S.A. | Phase 2/3 | Terminated | COVID-19 | 509 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04393038) |
| August 8, 2019 | NCT04049448 | Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis | Abivax S.A. | Phase 2 | Completed | Rheumatoid Arthritis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04049448) |
| July 17, 2019 | NCT04023396 | Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis | Abivax S.A. | Phase 2 | Completed | Ulcerative Colitis | 217 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04023396) |
| April 5, 2019 | NCT03905109 | Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients | Abivax S.A. | Phase 2/3 | Withdrawn | Crohn Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03905109) |
| April 1, 2019 | NCT03897543 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | Abivax S.A. | Phase 1/2 | Completed | Carcinoma, Hepatocellular | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03897543) |
| January 23, 2019 | NCT03813199 | Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis | Abivax S.A. | Phase 2 | Completed | Rheumatoid Arthritis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03813199) |
| November 30, 2018 | NCT03760003 | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis | Abivax S.A. | Phase 2 | Completed | Ulcerative Colitis | 355 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03760003) |
| December 11, 2017 | NCT03368118 | Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis | Abivax S.A. | Phase 2 | Completed | Ulcerative Colitis | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03368118) |
| March 28, 2017 | NCT03093259 | ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis | Abivax S.A. | Phase 2 | Completed | Ulcerative Colitis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03093259) |
| December 13, 2016 | NCT02990325 | A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults | Abivax S.A. | Phase 1/2 | Completed | HIV Infections, Health Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02990325) |
| June 7, 2016 | NCT02792686 | ABX464 First in Man Study | Abivax S.A. | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02792686) |
| April 13, 2016 | NCT02735863 | ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment | Abivax S.A. | Phase 2 | Completed | HIV Infection | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02735863) |
| April 8, 2016 | NCT02731885 | Food Effect on Pharmacokinetic Parameters of ABX464 | Abivax S.A. | Phase 1 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02731885) |
| May 22, 2015 | NCT02452242 | Safety, PK and PD Study of ABX464 in Untreated HIV Patients | Abivax S.A. | Phase 2 | Completed | Human Immunodeficiency Virus Infections | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02452242) |
| September 26, 2014 | NCT02249988 | Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B | Abivax S.A. | Phase 2/3 | Completed | Chronic Hepatitis B | 261 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02249988) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 2 |
| Phase 2 | 10 |
| Phase 2/3 | 3 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Active not recruiting | 2 |
| Recruiting | 2 |
| Withdrawn | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Colitis, Ulcerative | 8 |
| HIV Infections | 2 |
| Arthritis, Rheumatoid | 2 |
| Crohn Disease | 2 |
| Carcinoma, Hepatocellular | 1 |
| COVID-19 | 1 |
| Hepatitis B, Chronic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Charter schools in the United States](https://specstream.ai/data/businesses/charter-schools/united-states)
- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
- [Georgian restaurants in the United States](https://specstream.ai/data/businesses/georgian-restaurants/united-states)
- [Appliance repair companies in the United States](https://specstream.ai/data/businesses/appliance-repair-companies/united-states)
- [Occupational therapy clinics in the United States](https://specstream.ai/data/businesses/occupational-therapy-clinics/united-states)
- [Customs brokers in the United States](https://specstream.ai/data/businesses/customs-brokers/united-states)
